cilostazol has been researched along with vorapaxar in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Diener, HC; Weber, R | 1 |
| Abosheasha, MA; El-Gowily, AH; Elfiky, AA | 1 |
1 review(s) available for cilostazol and vorapaxar
| Article | Year |
|---|---|
Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention.
Topics: Aspirin; Blood-Brain Barrier; Cilostazol; Clopidogrel; Dipyridamole; Drug Interactions; Drug Therapy, Combination; Humans; Lactones; Naphthalenes; Platelet Aggregation Inhibitors; Propionates; Pyridines; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke; Succinates; Tetrazoles; Thrombosis; Ticlopidine | 2010 |
1 other study(ies) available for cilostazol and vorapaxar
| Article | Year |
|---|---|
Potential antiviral properties of antiplatelet agents against SARS-CoV-2 infection: an in silico perspective.
Topics: Antiviral Agents; Cilostazol; Coronavirus 3C Proteases; COVID-19 Drug Treatment; Humans; Lactones; Molecular Docking Simulation; Molecular Dynamics Simulation; Platelet Aggregation Inhibitors; Pyridines; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Ticagrelor | 2022 |